Share on facebook
Share on twitter
Share on linkedin

February 2019: BioAegis Therapeutics Announces Publication in “Clinical Infectious Diseases” Linking Depleted Plasma Gelsolin Concentrations at Admission to Severe Pneumonia Outcomes in CDC-Sponsored “Etiology of Pneumonia in the Community (EPIC)” Study

MORRISTOWN, N.J., Feb. 01, 2019 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc. announced the publication of a paper in Clinical Infectious Disease—a journal of the Infectious Disease Society of America entitled, Low Admission Plasma Gelsolin Concentrations Identify Community-acquired Pneumonia (CAP) Patients at High Risk for Severe Outcomes.  BioAegis, together with Investigators at Vanderbilt and Northwestern Universities as well as the CDC, retrospectively analyzed samples from the previously completed CDC-Sponsored EPIC study that prospectively followed several thousand CAP patients.

Read the full press release here: Publication in “Clinical Infectious Diseases”